Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 123202522 | 12320252 | 2 | F | 20160421 | 20160429 | 20160720 | EXP | CH-MYLANLABS-2016M1017783 | MYLAN | DARUICH A, MATET A, DIRANI A, GALLICE M, NICHOLSON L, SIVAPRASAD S, ET AL. ORAL MINERALOCORTICOID-RECEPTOR ANTAGONISTS: REAL-LIFE EXPERIENCE IN CLINICAL SUBTYPES OF NONRESOLVING CENTRAL SEROUS CHORIORETINOPATHY WITH CHRONIC EPITHELIOPATHY. TRANSL-VIS-SCI-TECHNOL 2016;5:NO. 2. | 0.00 | Y | 0.00000 | 20160720 | OT | CH | CH |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 123202522 | 12320252 | 1 | PS | SPIRONOLACTONE. | SPIRONOLACTONE | 1 | Oral | 50MG DAILY | 40424 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 123202522 | 12320252 | 1 | Chorioretinopathy |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 123202522 | 12320252 | Hyperkalaemia | |
| 123202522 | 12320252 | Off label use |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |